Accuray

Accuray, Inc. is a radiation oncology company. It engages in the development, manufacture and sale of treatment solutions that includes CyberKnife and Tomo Therapy systems, designed to deliver radiosurgery, stereotactic body radiation therapy, intensity modulated radiation therapy, image-guided radiation therapy, and adaptive radiation therapy. The company was founded by John R. Adler in 1990 and is headquartered in Sunnyvale, CA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Accuray reports strong Q1 2023 earnings and focuses on global expansion

Accuray's Q1 2023 earnings call highlighted strong financial performance, with significant revenue growth and increased system orders. The company is focused on driving profitability expansion and expanding patient access to its technologies worldwide. While facing challenges in managing backlog and addressing performance in China, Accuray is actively pursuing opportunities for margin expansion and business growth.

Accuray delivers record Q2 performance, eyes growth opportunities ahead

Accuray's Q2 2023 performance highlighted record system deliveries and strong order growth, with a focus on radiation oncology services.
Despite challenges in revenue decline and backlog, strategic wins and progress in key regions position the company for future growth.
Opportunities lie in market expansion in the Americas, strategic wins in key regions, and advancements in China.
Maintaining growth momentum, addressing revenue challenges, and capitalizing on opportunities are key focus areas for Accuray.

Accuray reports strong Q3 earnings, eyes global expansion and partnerships

Accuray's Q3 2023 earnings call showcased robust financial performance, strategic initiatives to drive profitability, and a commitment to global expansion. Despite challenges in product positioning and market competition, the company's focus on innovation and partnerships positions it well for future growth and market leadership.

Accuray reports 8% revenue growth, eyes margin expansion and growth

Accuray's Q4 2023 performance showed revenue growth, strong demand for Radixact, and strategic order wins. While facing challenges in product margins and supply chain, the company aims for margin expansion and growth opportunities in the second half of FY '24. Implementation of a new ERP system is expected to drive operational efficiencies and profitability insights.

Accuray reports strong Q1 earnings, eyes growth in China and India

Accuray delivered a robust Q1 performance with revenue and EBITDA growth, backed by strategic wins in key markets like China and India. The company's focus on new product innovations and cost optimization efforts contributed to its positive results. While challenges related to inflation exist, Accuray remains optimistic about reimbursement changes and market opportunities.

Accuray reports strong Q2 performance with growth opportunities ahead

Accuray's Q2 2024 showcased robust order growth, service revenue increase, and global demand strength. The company is focused on margin expansion and new product market clearances for future growth.

Accuray faces challenges in Q3 2024 but remains optimistic

Accuray's Q3 2024 performance was impacted by challenges but showed resilience with global order growth and strategic focus on long-term goals. Despite revised guidance, the company remains optimistic about future growth drivers and is prepared for gradual recovery post-COVID.

Accuray reports robust Q1 performance and raises FY '25 guidance

Accuray's Q1 2025 performance reflects strong revenue growth, margin expansion efforts, and positive market reception for its innovative products and services.
While facing challenges in certain markets and regulatory timelines, the company remains optimistic about future revenue trends and growth opportunities globally.
By raising its revenue guidance and focusing on operational efficiency, Accuray aims to capitalize on market opportunities and navigate potential challenges effectively.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Accuray, Inc. is a radiation therapy company, which engages in manufacturing medical equipment. It develops, manufactures, sells, and supports medical solutions. The company was founded by John R. Adler in 1990 and is headquartered in Madison, WI.

Management sees revenue growing faster in the second half of the fiscal year.

Accuray Reports Solid Earnings in its Second Fiscal Quarter

Accuray (ARAY) delivered earnings and revenue surprises of 114.29% and 0.38%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Accuray (ARAY) Q2 Earnings and Revenues Beat Estimates

Intuitive Surgical

Which stock is the better option for investors looking to profit from the market for medical devices?

Better Buy: Intuitive Surgical vs. Accuray

Accuray (ARAY) reported earnings 30 days ago. What's next for the stock?

Accuray (ARAY) Up 10.9% Since Last Earnings Report: Can It Continue?

Accuray (ARAY) reiterates revenue and adjusted EBITDA view for fiscal 2020.

Accuray (ARAY) Q1 Wider Than Expected, FY20 View Retained

Accuray, Inc. (ARAY) CEO Douglas Sherk on Q1 2020 Results - Earnings Call Transcript

Accuray (ARAY) delivered earnings and revenue surprises of -10.00% and -4.03%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Accuray (ARAY) Reports Q1 Loss, Lags Revenue Estimates

Medtronic

Stereotaxis Inc

Stryker

Varian Medical Systems

Accuray and Stereotaxis are hyper-focused on growth.

High-Tech Robotic Surgery Gets Specialized

Accuray's (ARAY) CyberKnife delivers stereotactic body radiation therapy in only five sessions.

Accuray's (ARAY) CyberKnife Delivers Improved Patient Outcome

Why Is Accuray (ARAY) Down 1% Since Last Earnings Report?

Accuray (ARAY) slashes fiscal 2020 revenue guidance owing to tariffs in China.

Here's Why Investors Should Retain Accuray (ARAY) Stock Now

Accuray Inc (NASDAQ:ARAY) files its latest 10-K with SEC for the fiscal year ended on June 30, 2019.

Accuray Inc (ARAY) Files 10-K for the Fiscal Year Ended on June 30, 2019

Disappointing fourth-quarter results are taking a toll on the medical device stock.

Here's Why Accuray Stock Is Nosediving Today

Accuray (ARAY) expects fiscal 2020 revenues to be impacted by China tariffs.

Accuray (ARAY) Reports Loss in Q4, Revenues Beat Estimates

The CyberKnife maker missed Wall Street bottom-line estimates and announced disappointing guidance for fiscal 2020.

No Hooray for Accuray in Q4

Accuray Incorporated (ARAY) CEO Josh Levine on Q4 2019 Results - Earnings Call Transcript

Accuray (NASDAQ: ARAY) unveils its next round of earnings this Thursday, August 15.

Earnings Outlook For Accuray

Accuray (ARAY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Accuray (ARAY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Solid demand for Accuray's (ARAY) Radixact, CyberKnife and TomoTherapy platforms continue to boost business.

Accuray (ARAY) Q3 Earnings Top Estimates, Gross Orders Rise

Accuray Incorporated (ARAY) CEO Joshua Levine on Q3 2019 Results - Earnings Call Transcript

Which medical-device titan is more worthy of your investment dollars today?

News for Accuray Stock (ARAY)